Durata Therapeutics, Inc. has initiated enrollment of a Phase 3b clinical trial to evaluate the efficacy and safety of its investigational product, Dalvance™ (dalbavancin) for injection, in a single 1500 milligram dose infused over 30 minutes in adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria.
— UPCOMING EVENTS —
4/29 4:00 pm – 6:00 pm
Yale & CURE BioHaven presents ‘Melinta Therapeutics: The Road from the Lab to New Medicines’ … more
5/12 5:00 pm – 6:30 pm in New Haven
BioScienceClubhouseCT presents ‘SystaMedic: A Novel Cause-Effect Analysis Platform for Predicting Probability of R&D Program Success’ … more
6/5 4:00 pm – 6:00 pm in New Haven
BioHaven panel discussion and CURE Annual Meeting. Watch for details!